[1] Lee SL. Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes, 2012, 19(5): 420-428.  doi: 10.1097/MED.0b013e328357fa0c
[2] Waldhausen JH. Controversies related to the medical and surgical management of hyperthyroidism in children. Semin Pediatr Surg, 1997, 6(3): 121-127.
[3] Freitaz JE. The role of nuclear medicine in the management of Graves' disease. Q J Nucl Med, 1999, 43(4): 297-306.
[4]

中华医学会.临床技术操作规范(核医学分册).北京:人民军医出版社, 2004: 175-177.
[5] 中华医学会内分泌分会《中国甲状腺疾病诊断指南》编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症.中华内科杂志, 2007, 46(10): 876-882.  doi: 10.3760/j.issn:0578-1426.2007.10.035
[6] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识(2010年).中华核医学杂志, 2010, 30(5): 346-351.  doi: 10.3760/cma.j.issn.0253-9780.2010.05.019
[7] Bauer AJ. Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted?. J Clin Endocrinol Metab, 2011, 96(3): 580-588.  doi: 10.1210/jc.2010-0898
[8] Juki T, Stanici J, Petric V, et al. Radioiodine versus surgery in the treatment of Graves' hyperthyroidism. Lijec Vjesn, 2010, 132(11-12): 355-360.
[9] Peroni E, Angiolini MR, Vigone MC, et al. Surgical management of pediatric Graves' disease: an effective definitive treatment. Pediatr Surg Int, 2012, 28(6): 609-614.  doi: 10.1007/s00383-012-3095-5
[10] 赵德善, 孔繁振, 司宏伟, 等.儿童和青少年甲状腺机能亢进症的131I治疗.中华内分泌代谢杂志, 2006, 22(6): 566-568.  doi: 10.3760/j.issn:1000-6699.2006.06.017
[11]

Ma C, Kuang A, Xie J, et al. Radioiodine treatment for pediatric Graves' disease[DB/OL]. Cochrane Database Syst Rev, 2008[2012-10-23]. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006294.pub2/pdf.
[12] Rivkees SA. Pediatric Graves' disease: controversies in management. Horm Res Paediatr, 2010, 74(5): 305-311.  doi: 10.1159/000320028
[13] Flynn RW, Macdonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab, 2006, 91(6): 2159-2164.  doi: 10.1210/jc.2005-1833
[14] Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA, 2005, 294(1): 71-80.  doi: 10.1001/jama.294.1.71
[15] Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab, 2004, 89(9): 4229-4233.  doi: 10.1210/jc.2003-031223
[16] Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab, 2007, 92(3): 797-800.  doi: 10.1210/jc.2006-1239
[17] Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 2011, 21(6): 593-646.  doi: 10.1089/thy.2010.0417
[18] 马寄晓. 131I治疗甲状腺功能亢进症的远期观察.中华核医学杂志, 1984, 4(1): 7-11.
[19] Chao M, Jiawei X, Guoming W, et al. Radioiodine treatment for pediatric hyperthyroid Grave's disease. Eur J Pediatr, 2009, 168(10)1165-1169.  doi: 10.1007/s00431-009-0992-2
[20] 段东, 罗加, 李建国.青少年甲亢131I治疗后早发甲低的观察.重庆医学, 2004, 33(9): 1387-1388.  doi: 10.3969/j.issn.1671-8348.2004.09.058
[21] Zheng W, Jian T, Guizhi Z, et al. Analysis of 131I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study. Nucl Med Commun, 2012, 33(1): 97-101.
[22] 李佳, 秦岚, 任众, 等. 131I治疗青少年Graves病的量效分析.国际放射医学核医学杂志, 2010, 34(3): 152-155.  doi: 10.3760/cma.j.issn.1673-4114.2010.03.006